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Abstract 15 
Oxyntomodulin analogues offer a novel treatment for obesity. However during analogue 16 
screening in a rat model increased food intake was consistently observed. To further 17 
investigate this finding, a series of representative analogues (OXM14 and OXM15) and 18 
their Glu-3 equivalents (OXM14E3 and OXM15E3) were administered to rats for 7 days 19 
and food intake and bodyweight measurements taken. To investigate the role of glucagon 20 
receptor activation glutamate (Glu/E) was substituted at amino acid position 3. GLP-1 21 
and glucagon receptor efficacy of the oxyntomodulin analogues and their Glu-3 22 
counterparts were measured at the rat receptors in vitro.
 
Doses of 25nmol/kg of OXM14 23 
and OXM15 increased food intake by up to 20%. Bodyweight was not significantly 24 
increased. Food intake was not increased with the Glu-3 peptides, indicating that a 25 
glucagon receptor mechanism may be responsible for the increase in food intake.  26 
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1.0
1
Introduction 28 
Oxyntomodulin is the 29 amino acids of glucagon with an additional C-terminal 29 
octapeptide tail. It is a product of the proglucagon precursor peptide along with 30 
glucagon-like peptide-1 (GLP-1), glucagon and glucagon-like peptide-2 (GLP-2) and is 31 
co-secreted post prandially with GLP-1 from L-cells in the distal intestine [21] . A 32 
specific oxyntomodulin receptor has not been identified; the peptides proposed 33 
mechanism of action is by activation of both the glucagon and GLP-1 receptors, although 34 
with reduced efficacy compared to the native ligands [22,23,32] . In vivo studies have 35 
shown that peripheral administration of oxyntomodulin causes weight loss in rodents 36 
[1,5,6,25]  and humans [4,36,37]  and both glucagon and oxyntomodulin have been 37 
shown to increase energy expenditure in these species [7,19,34,36,37] . Based on 38 
findings in mice it has been suggested that oxyntomodulin reduces food intake via 39 
activity at the GLP-1 receptor, while its activity at the glucagon receptor causes weight 40 
loss by increasing energy expenditure [25]. Glucagon stimulates glycogenolysis and 41 
gluconeogenesis, elevating blood glucose, and administration of glucagon causes 42 
hyperglycaemia [3] . However, oxyntomodulin administration does not elevate blood 43 
glucose [36,37] . Recent studies have suggested that chronic oxyntomodulin 44 
administration improves glucose tolerance by increasing insulin secretion via the GLP-1 45 
receptor and additionally by reducing weight [12,25] .  46 
Despite the beneficial effects of oxyntomodulin on weight and glucose homeostasis, the 47 
very short half-life of native oxyntomodulin means it is not used therapeutically [24]. 48 
The proglucagon peptides, for example, are susceptible to degradation by the enzyme 49 
dipetidylpeptidase-IV (DPPIV) [39]. Our group, and several others, have reported that 50 
oxyntomodulin can be successfully modified to produce long acting analogues with 51 
sustained food intake reduction and enhanced body weight loss [2,11,23,26] .  52 
As part of a proprietary drug development program, analogues of oxyntomodulin were 53 
designed with modifications in regions susceptible to degradation. The changes made 54 
                                                          
1
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were conservative, thus the analogues were not derivatized, were of similar length to the 55 
native peptide, had no cross linkages and included only natural amino acids. All 56 
analogues were based on the 29 amino acids of glucagon and contained 5 to 7 single 57 
substitutions between residues 12-29, with 2 or 3 additional amino acid residues at the C-58 
terminal. During screening it was observed that when administered to rats, the numerous 59 
analogues tested did cause significant reductions in bodyweight but, unexpectedly had 60 
either no effect on food intake, or actually caused an increase. The current paper focuses 61 
on a representative sample of these oxyntomodulin analogues to further investigate the 62 
mechanism behind the increase in food intake and to assess the impact these findings 63 
might have on the design and therapeutic use of oxyntomodulin analogues. 64 
 65 
2.0 Materials and methods 66 
2.1 Peptides 67 
All oxyntomodulin analogues tested (OXM8, OXM9, OXM10, OXM14, OXM15, 68 
OXM14E3, OXM15E3) and native peptides (Exendin-4 and human glucagon, 69 
GLP-1(7-36NH2) and oxyntomodulin) were custom synthesized by Insight Biotechnology 70 
Limited (Middlesex, UK) using solid phase peptide synthesis (SPPS) methodology and 71 
purified by reverse-phase preparative HPLC. Peptide purity was determined by reverse-72 
phase HPLC and by Matrix-assisted laser desorption ionization mass spectroscopy 73 
(MALDIMS). All peptides had a purity of >90%. 74 
 75 
2.2 In vitro cAMP accumulation 76 
The effects of oxyntomodulin analogues and native GLP-1, glucagon and oxyntomodulin 77 
on cyclic adenosine monophosphate (cAMP) accumulation were assessed in Chinese 78 
hamster ovary (CHO-K1) cells over-expressing the rat glucagon receptor (cDNA from 79 
Origene, Maryland, USA) and Chinese hamster lung (CHL) cells over-expressing the rat 80 
GLP-1 receptor (a kind gift from Professor Bernard Thorens, University of Lausanne, 81 
Switzerland). For cAMP studies, cells were seeded at a density of 150 000cells/ml in a 82 
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48 well plate (Nunc, VWR International Inc, Chicago, USA) and incubated for 24 hours. 83 
Cells were serum starved for 1 hour and then incubated for 30 minutes at room 84 
temperature with a range of peptide concentrations diluted in serum free DMEM (Sigma-85 
Aldrich, Dorset, UK) in the presence of 1mM IBMX (3-isobutyl-1-methylxanthine, 86 
Sigma-Aldrich). After incubation, medium was removed and cells lysed with 0.1M HCl 87 
+ 0.5% Triton-X. cAMP levels were measured using an ELISA kit according to 88 
manufacturer’s instructions (ADI-900-066, Enzo Life Sciences, New York, USA), 89 
optical density was read at 405nm on a Biotek ELx808 (Wolf Laboratories, York, UK). 90 
EC50’s were calculated using Prism v5 (GraphPad Software Inc. San Diego, CA, USA). 91 
Concentrations were applied in duplicate or triplicate per experiment and each 92 
experiment repeated a minimum of 3 times. 93 
 94 
2.3 Animals 95 
Male Wistar rats (Charles River, Margate, UK) were maintained in individual cages 96 
under controlled temperature (21-23C) and light conditions (12:12 light-dark cycle, lights 97 
on at 0700 hours) with ad-libitum access to food (RM1 diet; SDS, Witham, UK) and 98 
water unless otherwise stated. All animal procedures were approved under the British 99 
Home Office Animals (Scientific Procedures) Act 1986 (Project License 70/7236). 100 
 101 
2.4 Seven day food intake and bodyweight studies 102 
Rats were weighed at 0900 on the morning of study commencement and randomisation 103 
to treatment groups was stratified by bodyweight. A subcutaneous injection of vehicle 104 
(diluent) or peptide (maximum volume 100µl/kg, reconstituted in ZnCl2 slow release 105 
formulation) was administered at 1600 hours daily and food and bodyweight measured at 106 
the time of administration. A minimum of 7 animals per group was required based on 107 
previous observations. n numbers varied between experiments, see figure legends for the 108 
exact sample size of each group. 109 
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2.5 Statistical analysis 110 
All food and bodyweight data are presented as mean ± SEM. Data was normally 111 
distributed according to the D’Agostino & Pearson omnibus normality test or the 112 
Shaprio-Wilk normality test for groups where n=7. Between group variances were 113 
similar according to Bartlett’s test for equal variances. Differences in 0-7 day cumulative 114 
food intake and bodyweight data were analysed using one way ANOVA and post hoc 115 
tests with Dunnett’s or Bonferroni corrections for multiple comparisons (Prism v5, 116 
GraphPad Software Inc. San Diego, CA, USA). cAMP EC50’s were calculated using a 117 
sigmoidal dose response curve and non-linear regression (Prism v5). EC50 data is 118 
presented as a ratio of analogue average EC50/average glucagon EC50 or GLP-1 EC50. 119 
Average EC50’s were calculated from a minimum of 3 separate experiments. In all cases 120 
P < 0.05 was considered statistically significant. 121 
 122 
3.0 Results 123 
3.1 Oxyntomodulin and analogues favour glucagon receptor activity at the rat receptors 124 
At the rat receptors, oxyntomodulin and analogues showed greater efficacy at the 125 
glucagon receptor than the GLP1 receptor (Table 1). The analogues had greater activity 126 
than oxyntomodulin at both the rat glucagon and GLP-1 receptors. The Glu-3 peptides 127 
OXM14E3 and OXM15E3 had similar efficacy at the rat GLP-1 receptor compared to 128 
OXM14 and OXM15 respectively, however their efficacies at the rat glucagon receptor 129 
were 165 and 27 fold lower respectively (Table 1).  130 
 131 
 132 
 133 
 134 
 135 
 136 
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Table 1. cAMP EC50 ratios 
   
  
  EC50 ± SEM (nM) 
EC50 ratio to native 
peptide (arbitrary units) 
  Rat Gcgr Rat GLP-1r Rat Gcgr Rat GLP-1r 
GLP-1 >1000 0.08 ± 0.01 ND 1.0 
Exendin-4 >1000 0.06 ± 0.01 ND 0.75 
Glucagon 0.34 ± 0.04 23.4 ± 5.88 1.0 297.2 
OXM 11.4 ± 2.81 9.10 ± 0.40 33.1 115.7 
OXM8 0.21 ± 0.05 2.18 ± 0.43 1.2 13.7 
OXM9 0.48 ± 0.11 4.38 ± 0.81 0.6 27.7 
OXM10 0.40 ± 0.10 1.08 ± 0.15 1.4 55.7 
OXM15 0.38 ± 0.09 4.39 ± 1.17 1.1 55.8 
OXM15E3 10.1 ± 1.66 6.99 ± 0.29 29.3 88.9 
OXM14 0.23 ± 0.03 1.49 ± 0.25 0.7 19.0 
OXM14E3 39.9 ± 2.61 2.18 ± 0.06 115.8 27.7 
EC50 values for cAMP accumulation measured in CHO-K1 cells over expressing the rat 137 
glucagon receptor, or CHL cells over expressing the rat GLP-1 receptor after 30 minute 138 
peptide stimulation. EC50’s for each peptide were calculated from the average EC50’s 139 
from 3-5 independent experiments. Receptor efficacy at the rat glucagon receptor is 140 
also expressed as a ratio of the EC50 of glucagon and of the EC50 of GLP1 at the rat GLP-1 141 
receptor. A ratio value below 1 indicates enhanced efficacy, and above 1 decreased 142 
efficacy compared to the native peptide. ND – not determined, OXM – oxyntomodulin, 143 
Gcgr – glucagon receptor, GLP-1r – GLP-1 receptor. 144 
 145 
3.2 Oxyntomodulin analogues reduce bodyweight without reducing food intake 146 
A daily dose of 25nmol/kg OXM15 caused a significant 17% increase in cumulative food 147 
intake by the end of the 7 day treatment period compared to vehicle controls (P < 0.001; 148 
n=7-8; Figure 1A).  149 
Daily administration of 25nmol/kg OXM8, OXM9 and OXM10, significantly reduced 7 150 
day bodyweight by 4-6% compared to vehicle controls (OXM8: P < 0.01, OXM9: 151 
P < 0.001, OXM10: P < 0.001; n=7-8; Figure 1B).  152 
Seven day food intake was significantly increased in all groups administered daily 153 
25nmol/kg
 
doses of OXM analogues compared to 5nmol/kg Exendin-4 (P < 0.001; 154 
Figure 1A).  155 
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 156 
Figure 1. Daily S/C 25nmol/kg oxyntomodulin analogue administration increased 157 
cumulative 7 day food intake (A) and reduced bodyweight (B) compared to vehicle 158 
administration. Average starting weight 506g. Vehicle, OXM9, OXM10 n=8/group; all 159 
other groups n=7/group. Data represent mean ± SEM. Significance calculated using one 160 
way ANOVA (A, F = 16.78, P < 0.0001; B, F = 5.074, P = 0.0011) with Bonferroni post hoc 161 
test (*P <0.05, ***P <0.001 vs vehicle controls, # # #P < 0.001 vs Exendin-4 group). 162 
 163 
3.3 Lower doses of OXM14 and OXM15 reduce weight gain without decreasing food 164 
intake 165 
There was a dose dependent decrease in bodyweight during 7 day administration of 166 
OXM15 and similar analogue OXM14. There was trend towards a dose dependent 167 
increase in food intake with lower doses of both OXM14 and OXM15 compared to 168 
vehicle controls. Doses of 12-, 25- and 50nmol/kg of OXM14 non significantly increased 169 
food intake by 5%, 11% and 12% respectively compared to vehicle controls (Figure 2A). 170 
A daily 100nmol/kg dose of OXM14 significantly decreased food intake by 23% 171 
compared to vehicle controls (P <0.05, Figure 2A). Doses of 12- and 25nmol/kg 172 
decreased 7 day bodyweight non significantly by 1.2% and 1.7% respectively compared 173 
to vehicle controls. Doses of 50nmol/kg and 100nmol/kg of OXM14 significantly 174 
decreased bodyweight by 5% and 12% respectively compared to controls. (P < 0.05, P < 175 
0.001; n= 8-9; Figure 2B). 176 
Doses of 10-, 15- and 25nmol/kg of OXM15 increased 7 day food intake by 4%, 5% and 177 
8% respectively compared to vehicle controls. A daily 50nmol/kg dose of OXM15 non 178 
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significantly decreased food intake by 12% compared to controls (Figure 3A). Seven day 179 
bodyweight was non significantly decreased by 1.4% by daily administration of 180 
25nmol/kg OXM15 (Figure 3B). Daily doses of 35nmol/kg and 50nmol/kg OXM15 181 
significantly reduced 7 day bodyweight by 5% and 8% respectively compared to controls 182 
(P < 0.001; n= 9-10; Figure 3B). 183 
 184 
185 
Figure 2. Cumulative 7 day food intake (A) and body weight change (B) in response to 186 
daily SC injections of various doses of OXM14 or vehicle. Average starting weight 577g. 187 
Vehicle n=9/group; all other groups n=8/group. Data represent mean ± SEM. 188 
Significance calculated using one way ANOVA (A, F = 4.64, P = 0.0018; B, F = 13.58, P < 189 
0.0001) with Dunnett’s post hoc test (*P <0.05, ***P <0.001 vs vehicle controls). 190 
 191 
 192 
Figure 3. Cumulative 7 day food intake (A) and bodyweight change (B) after daily 193 
administration of OXM15 at various doses. Average starting weight 542g. Vehicle, 194 
OXM(50), OXM(10) n=9/group; all other groups n=10/group. Data represent mean ± 195 
SEM. Significance calculated using one way ANOVA (A, F = 3.503, P = 0.0089; B, F = 196 
27.13, P < 0.0001) with Dunnett’s post hoc test (***P <0.001 vs vehicle controls).  197 
 198 
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3.4 No increased food intake with reduced glucagon receptor activity  199 
To further investigate the effects of glucagon receptor activity on food intake, OXM14 200 
and OXM15 were re-synthesized with the position 3 glutamine (Gln/Q) substituted for 201 
glutamate (Glu/E). This substitution had previously been reported to significantly 202 
diminish glucagon receptor activity without affecting GLP-1 receptor activity [12] . In-203 
line with previous findings using Glu-3 peptides, the efficacy of OXM14E3 and 204 
OXM15E3 at the glucagon receptor were 173 and 27 times lower compared to OXM14 205 
and OXM15 respectively, while their GLP1r activity was unaffected (Table 1). 206 
As seen in the previous experiments; repeated daily administration of 25nmol/kg 207 
OXM15 significantly increased cumulative food intake over 7 days by 20% (P < 0.01), 208 
and OXM14 increased cumulative food intake by 19% (P < 0.05; n= 7; Figure 4). 209 
Neither OXM14E3 or OXM15E3 significantly increased cumulative food intake 210 
compared to vehicle controls (Figure 4). 211 
 212 
 213 
Figure 4. Cumulative 7 day food intake in response to daily 25nmol/kg SC injections of 214 
OXM14, OXM14E3, OXM15, OXM15E3 or vehicle. Vehicle n=8/group; all other groups 215 
n=7. Data represent mean ± SEM. Significance calculated using one way ANOVA 216 
(F = 5.258, P = 0.0029) with Dunnett’s post hoc test (*P <0.05, **P <0.01 vs vehicle 217 
controls). 218 
 219 
 220 
 221 
 222 
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4.0 Discussion 223 
This study suggests that analogues of oxyntomodulin can cause an increase in food 224 
intake in rats while generating significant reductions in bodyweight, and that the 225 
increased consumption may involve a glucagon receptor mediated mechanism. This 226 
finding seems to be a rat specific phenomenon which may be of interest in the 227 
development of oxyntomodulin analogues for therapeutic treatment of obesity in humans. 228 
Previous studies have reported the use of oxyntomodulin analogues with a glutamate at 229 
amino acid position 3 as a tool to investigate the contribution of glucagon receptor 230 
activity to the effects on food intake and bodyweight. Thus, changing the position 3 231 
glutamine of oxyntomodulin to glutamate (as found in GLP-1 and its natural analogue 232 
exendin-4) severely diminishes glucagon receptor activity without affecting the activity 233 
at the GLP-1 receptor, essentially producing a GLP-1 receptor selective analogue 234 
[12,25,31] . Comparing the effects of oxyntomodulin analogues with their Glu-3 235 
counterparts in a chronic study therefore enables investigation of the contribution of 236 
glucagon receptor activity to oxyntomodulin function. In the current study, no increase in 237 
food intake was seen with GLP-1 selective Glu-3 analogues OXM14E3 and OXM15E3, 238 
suggesting that a glucagon receptor mechanism may be involved in mediating the 239 
increase in food intake. An increase in energy expenditure is seen following peripheral 240 
administration of glucagon in rodents [8] and humans [34]. Therefore in the current study 241 
the increase in food intake may be a compensatory response to a chronic increase in 242 
energy expenditure. A similar pattern of increased food intake without an increase in 243 
bodyweight is observed in patients with thyrotoxicosis and this is generally accepted to 244 
be a compensatory response to the hypermetabolic state induced by high levels of thyroid 245 
hormone [13]. A previous study has reported an acute hyperphagic response to IP 246 
glucagon administration in rats [18]  and they attributed this to the low dose of 50µg/kg 247 
(14nmol/kg) that was used. Although glucagon has been suggested to acutely reduce 248 
food intake, this is typically observed following administration of higher doses 249 
[15,17,20,30]. Also, several studies that have reported an acute reduction in food intake 250 
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administered glucagon directly into the portal circulation [14,16,29,35]. This could have 251 
produced different effects on food intake as it would have resulted in high glucagon 252 
levels local to the liver and could be considered less physiological than peripheral 253 
administration.  No previous studies have investigated the effects of chronic exposure to 254 
glucagon on rodent food intake, probably due to the difficulties imposed by glucagon’s 255 
short half-life.  256 
Previous studies using native oxyntomodulin and longer lasting dual analogues have 257 
reported a reduction in food intake after repeated peripheral administration in rodents 258 
[6,9,10,23,26,31]  and humans [36,37] . The range of OXM14 and OXM15 doses that 259 
increase food intake are quite narrow and are generally lower than the doses of 260 
50nmol/kg
 
[6] , 1100nmol/kg [25]  and 1400nmol/kg [23]  of oxyntomodulin used in 261 
several prior chronic studies. Additionally, methods of peptide administration differ: 262 
some studies infused peptides [25]  while others administered peptide every 2-4 days 263 
[9,31]  or twice daily [6,28]. Liu et al [26] did administer their dual analogue to rats at 264 
lower doses of 5nmol/kg and 20nmol/kg. However, their particular analogue had a much 265 
greater efficacy at the GLP-1 receptor, compared to the oxyntomodulin analogues in the 266 
current study, therefore any potential increase in food intake could have been masked by 267 
enhanced GLP-1 receptor activity causing a dominant reduction in food intake. Both 268 
native glucagon and oxyntomodulin have short half-lives and are also unstable in 269 
solution which makes it difficult to study the effects of chronic administration; Alzet 270 
pumps are problematic and frequent injections would involve significant handling and 271 
consequential animal stress.  272 
Interestingly, the increase in food intake with low doses of oxyntomodulin analogues was 273 
not replicated in a mouse model (unpublished observations), indicating that this could be 274 
a species specific effect. A number of previous studies with oxyntomodulin analogues 275 
have been carried out using only mouse models [9,23,27,28,31], but there is no evidence 276 
as to whether human responses are more similar to rats or mice. These findings highlight 277 
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the importance of testing in more than one model, particularly for dual analogues where 278 
differential efficacy may occur.  279 
Oxyntomodulin activates both the human glucagon receptor and GLP-1 receptor with 280 
reduced efficacy compared to the native peptides [22,23,32]. There is a paucity of 281 
information in published literature comparing native oxyntomodulin activity at the rat 282 
glucagon receptor and rat GLP-1 receptor. Similar to previous findings at the human [23]  283 
and mouse [25]  receptors, we observed that oxyntomodulin activity at the rat receptors 284 
favoured glucagon receptor activity. The oxyntomodulin analogues studied in the current 285 
paper also favoured glucagon receptor activity, but with greater efficacy at both rat 286 
receptors compared to native oxyntomodulin.  287 
There was a trend towards an increase in food intake with low doses of both analogues 288 
up to a ‘threshold dose’, beyond which food intake was then decreased. It could be 289 
postulated that the threshold point may reflect the dose at which there is sufficient GLP1r 290 
activity to cause a reduction in food intake. There is a difference in threshold dose 291 
between OXM14 and OXM15 with a higher dose of OXM14 required to cause a 292 
reduction in food intake. It is likely this can be attributed to differences in their ratio of 293 
rat GLP-1 receptor to rat glucagon receptor activity. However, OXM14 has a greater 294 
efficacy at the rat GLP-1 receptor than OXM15 which would suggest a lower dose would 295 
be required to reduce food intake, thus highlighting the likelihood of a complex 296 
underlying interaction.   297 
Exendin-4 is a naturally occurring GLP-1 receptor selective agonist with a longer 298 
half-life. The weight loss caused by administration of this peptide in standard chow fed 299 
animals is thought to be mainly due to reduction in food intake [33,38] . In the initial 300 
experiment, all groups administered oxyntomodulin analogues lost similar amounts of 301 
weight as the exendin-4 group despite eating significantly more food. This indicates that 302 
the weight loss caused by the oxyntomodulin analogues may be due to increased energy 303 
expenditure as a result of glucagon receptor activity. With both OXM14 and OXM15 304 
there was a trend towards a dose dependent reduction in bodyweight. At lower doses, 305 
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food intake tended to increase as bodyweight decreased; indicating that below the 306 
‘threshold point’ bodyweight loss is likely to be due to this proposed increased energy 307 
expenditure mediated via glucagon receptor activity. OXM15 has a similar ratio of 308 
activity at the rat glucagon receptor and rat GLP-1 receptor as OXM10 as well as a 309 
similar pharmacokinetic profile; however OXM15 significantly increased food intake 310 
despite generating less weight loss than OXM10. This suggests that the underlying 311 
receptor interactions involved with oxyntomodulin-like dual analogues, and probably 312 
oxyntomodulin, are complex and could include the degree of access to CNS appetite and 313 
energy expenditure controlling centres. Co-administration of glucagon and GLP-1 in 314 
rodents [30]  and man [3]  appears to produce synergistic effects on food intake, 315 
indicating probable interaction of the two peptides.  316 
 317 
5.0 Conclusion 318 
We have shown that in a rat model low doses of oxyntomodulin analogues often tend to 319 
increase food intake without increasing bodyweight. . Results with GLP-1 receptor 320 
selective Glu-3 analogues suggest that a glucagon receptor mediated mechanism may be 321 
involved in the increase in food intake. It is possible that the increase in food intake may 322 
be a compensatory response to an increase in energy expenditure mediated by glucagon 323 
receptor activity. It is currently unclear what impact these findings may have on the use 324 
of oxyntomodulin analogues in a clinical setting. Nausea limits the dose of GLP-1 325 
analogues that can be used in man. It is unlikely that nausea is a feature of the 326 
oxyntomodulin analogues studied here, given the increase in food intake; however a 327 
conditioned taste aversion study in rats would help to clarify this.. 328 
 329 
 330 
 331 
 332 
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6.0 Glossary 333 
Hyperglycaemia – High blood sugar. 334 
Hyperphagic – Increases food intake. 335 
Gluconeogenesis – A metabolic pathway resulting in the production of glucose 336 
from non-carbohydrate carbon substrates. 337 
Glycogenolysis – The breakdown of glycogen stores to produce glucose. 338 
 339 
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